Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $195 | $213 | $200 | $188 |
| % Growth | -8.5% | 6.3% | 6.7% | – |
| Cost of Goods Sold | $79 | $82 | $87 | $114 |
| Gross Profit | $116 | $131 | $113 | $74 |
| % Margin | 59.7% | 61.4% | 56.4% | 39.5% |
| R&D Expenses | $9 | $11 | $11 | $10 |
| G&A Expenses | $54 | $60 | $44 | $12 |
| SG&A Expenses | $125 | $126 | $110 | $77 |
| Sales & Mktg Exp. | $71 | $66 | $66 | $65 |
| Other Operating Expenses | $0 | $0 | $0 | $26 |
| Operating Expenses | $134 | $137 | $120 | $113 |
| Operating Income | -$17 | -$6 | -$100 | -$132 |
| % Margin | -8.8% | -3% | -50% | -70.1% |
| Other Income/Exp. Net | -$51 | -$8 | -$15 | $57 |
| Pre-Tax Income | -$69 | -$15 | -$115 | -$75 |
| Tax Expense | $2 | $5 | -$17 | -$4 |
| Net Income | -$68 | -$26 | -$104 | -$71 |
| % Margin | -35% | -12% | -51.7% | -37.5% |
| EPS | -0.89 | -0.25 | -1.18 | -0.87 |
| % Growth | -256% | 78.8% | -35.6% | – |
| EPS Diluted | -0.89 | -0.25 | -1.24 | -0.87 |
| Weighted Avg Shares Out | 77 | 101 | 83 | 81 |
| Weighted Avg Shares Out Dil | 79 | 79 | 79 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $6 | $4 |
| Interest Expense | $35 | $0 | $5 | $2 |
| Depreciation & Amortization | $34 | $30 | $30 | $38 |
| EBITDA | $18 | $25 | $23 | -$110 |
| % Margin | 9% | 11.5% | 11.7% | -58.8% |